Last reviewed · How we verify
NCT05214105: PREMIER
The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia
trial testing Biospecimen/DNA collection and analysis in Sickle Cell Disease in 400 participants. Status unknown.
31 January 2026
Quick facts
| Lead sponsor | University of Tennessee |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 5 July 2022 |
| Primary completion | 31 January 2026 |
| Estimated completion | 31 January 2026 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Biospecimen/DNA collection and analysis
Conditions studied
- Sickle Cell Disease — all drugs for Sickle Cell Disease →
- Kidney Diseases, Chronic — all drugs for Kidney Diseases, Chronic →
Sponsor
University of Tennessee
Who can join
Adults 18 to 65, any sex, with Sickle Cell Disease or Kidney Diseases, Chronic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter prospective, longitudinal cohort study which will evaluate the predictive capacity of machine learning (ML) models for progression of CKD in eligible patients for a minimum of 12 months and potentially for up to 4 years.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05214105
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sickle Cell Disease
Currently open trials in the same condition.
- NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
- NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
- NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
- NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
- NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting
Other University of Tennessee trials
Trials by the same sponsor.
- NCT07465432 — Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries · Phase 4 · recruiting
- NCT07225725 — Access to Care Pilot for ED-Presenting Head and Neck Cancer Patients (ENRICH-HNC) · NA · not yet recruiting
- NCT07227519 — Effects of UPF Warning Labels on Social Media Among Teens and Young Adults · NA · not yet recruiting
- NCT06850857 — Multi-Institutional IMPACT Validation · enrolling by invitation
- NCT06745180 — Making Healthy Habits Stick · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05214105 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Tennessee
- Last refreshed: 14 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05214105.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing